• BullFrog AI outlined a shift toward commercialization and enterprise adoption of its bfLEAP, bfPREP, and bfARENAS drug intelligence platform.
• Highlighted a first commercial agreement with a Top 5 global pharmaceutical company, positioned as early validation for broader pharma R&D deployments.
• Reiterated a scalable revenue model built on upfront fees, milestones, and royalties tied to discovery and clinical-trial optimization work.
• Stated its balance sheet supports strategic priorities into late 2027, targeting expansion of commercial deals, contracts, and partnerships with large pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.